- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02028455
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Upon meeting the eligibility requirements and enrolling on study, subjects will undergo apheresis to obtain the T cells for the generation of the CD19 CAR+ T cells. In patients with a prior history of allogeneic HCT, the T cells obtained are of donor origin. The T cells are isolated from the apheresis product, the CD4 and CD8 T cells are then selected and grown separately, transduced with a lentivirus to express the CD19 CAR as well as a truncated EGFR that has no signaling capacity (noted EGFRt) and expanded in culture over a three week period. During the process of cell generation, subjects will continue to be cared for by their primary oncologist and may undergo additional treatment directed at the leukemia during this time.
After the CAR+ T cells have been generated, the subject undergoes a disease assessment and determination if lymphodepletion is necessary. A variety of lymphodepletion strategies are acceptable and determined on a case by case basis. At least 48 hours after the completion of lymphodepletion, the subject will receive and infusion of CAR+ T cells at an approximate 1:1 ratio of CD4 to CD8 CAR+ T cells.
Following treatment with the CAR+ T cells, subjects will be followed intensely for 2 months with serial blood testing and re-evaluation of disease status with bone marrow aspirates. After 2 months, the subjects clinical care will be resumed by their primary oncologist, and it is possible that they would receive additional chemotherapy or HCT.
Some subjects will receive cetuximab for ablation of the genetically modified T cells. Criteria to receive cetuximab include acute toxicities that are life threatening, as well as an ongoing remission with continued B cell aplasia.
Upon completion of the study, subjects will be followed bi-annually for 5 years, and then annually for 10 additional years with either a medical history, physical exam and blood tests or a phone call/questionnaire. This follow up will help to determine if the subject develops any long-term health problems related to the CAR+ T cells including a new cancer.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
Oakland, California, United States, 94609
- Children's Hospital Oakland
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients must be ≥12 months of age and <27 years of age at the time of study enrollment.
Must be ≥10kg
Confirmed CD19+ leukemia recurrence defined as ≥0.01% disease in the marrow or isolated extramedullary disease following allogeneic HCT. [N.B. Study closed to enrollment of leukemia subjects]
OR
No prior history of allogeneic HCT (one of the following)
- 2nd or greater relapse, with or without extramedullary disease (isolated extramedullary disease is eligible)
- 1st marrow relapse at end of 1st month of re-induction with marrow having ≥0.01% blast disease, with or without extramedullary disease
- Primary Refractory as defined as having M2 or M3 marrow after induction
- Subject has indication for HCT but has been deemed ineligible
OR
CD19+ Non-Hodgkin Lymphoma (NHL) refractory or relapsed with no known curative therapies available [N.B. Study remains open to enrollment of lymphoma subjects]
Patients with CNS involvement are eligible provided that they are asymptomatic and in the opinion of the study PI have a reasonable expectation that disease burden can be controlled in the interval between enrollment and T cell infusion. Patients that have a significant neurologic deterioration will be not be eligible for T cell infusion until alternate therapies result in neurological stabilization.
Patients must have a Lansky performance status score of ≥50 or a Karnofsky score of ≥ 50 for patients ≥16 years of age.
Life Expectancy of >8 weeks
Patients must be free from active GVHD and off immunosuppressive GVHD therapy for 4 weeks prior to enrollment.
Recovered from acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy
It must be at least 7 days since last chemotherapy was administered (this does not include intrathecal chemotherapy or maintenance chemotherapy)
No systemic corticosteroids (unless physiologic replacement dosing) within 7 days of enrollment.
No prior genetically modified cell therapy that is still detectable or virotherapy allowed.
- Normal serum creatinine based on age/gender
- Total bilirubin </3x ULN OR conjugated bilirubin </2mg/dl
- ALT </5X ULN
- SF of >28% by ECHO or EF >50% by MUGA
- ALC of >/= 100 cells/ul
- Pulse ox >/= 90% on room air
Patient must have documented negative HIV antigen and antibody, Hepatitis B surface antigen, and Hepatitis C antibody within 3 months prior to enrollment. For patient with positive Hepatitis C Ab, negative PCR testing must be documented in order to be eligible.
Patients must NOT have active clinically significant CNS dysfunction (including but not limited to such as uncontrolled seizure disorder, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder)
Must agree to highly effective contraception during and for 12 months after T cell infusion.
Patients must be able to tolerate apheresis procedure, including placement of temporary apheresis line if required.
Patients must NOT have an active malignancy other than CD19+ leukemia.
Patients must NOT have an active severe infection defined as:
- A positive blood culture within 48 hours of study enrollment
- A fever above 38.2 C AND clinical signs of infection within 48 hours of study enrollment
Patients must NOT have any concurrent medical condition that, in the opinion of the PI or designee, would prevent the patient from undergoing protocol-based therapy. Patients with a primary immunodeficiency/ bone marrow failure syndrome are excluded from this trial.
Research participant or parent/legal guardian must agree to participate in long-term follow-up for up to 15 years, if they are enrolled in the study and receive T-cell infusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1 - Cohort 1A
This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10^5 CAR T cells/kg
|
Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
|
Experimental: Phase 1 - Cohort 1B
This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10^6 CAR T cells/kg
|
Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
|
Experimental: Phase 1 - Cohort 1C
This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10^6 CAR T cells/kg
|
Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
|
Experimental: Phase 1 - Cohort 1D
This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10^7 CAR T cells/kg
|
Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
|
Experimental: Phase 1 - Cohort 1F1
This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 5x10^5 CAR T cells/kg following prescribed lymph-depletion with fludarabine and cyclophosphamide
|
Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
|
Experimental: Phase 1 - Cohort 1F2
This phase 1 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1x10^6 CAR T cells/kg following prescribed lymph-depletion with fludarabine and cyclophosphamide
|
Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
|
Experimental: Phase 2
The phase 2 cohort will receive Patient Derived CD19 specific CAR T cells at a dose of 1 x 10^6 CAR T cells/kg following lymphodepletion if indicated.
|
Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Experienced an Adverse Event Meeting the Dose-Limiting Toxicity Definition
Time Frame: Initial CAR T cell infusion through 30 days post infusion
|
The safety of the T cell infusion at the maximum tolerated dose determined in Phase 1, and further characterized in Phase 2, will be described
|
Initial CAR T cell infusion through 30 days post infusion
|
Number of Participants With an MRD Negative Complete Remission After Initial CAR T Cell Infusion
Time Frame: Initial CAR T cell infusion through Day 63 post infusion assessment (+/- 14 days)
|
The efficacy of the T cell infusion will be estimated based on the number of participants who have an MRD negative bone marrow aspirate following the initial T cell infusion
|
Initial CAR T cell infusion through Day 63 post infusion assessment (+/- 14 days)
|
Number of Participants Who Have a Releasable Cell Product Generated
Time Frame: Up to 28 days per manufacturing attempt
|
The feasibility of manufacturing and releasing T cell products from pediatric and young adult patients with CD19+ relapsed or refractory leukemia
|
Up to 28 days per manufacturing attempt
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Persistence of Functional CD19 CAR+ T Cells
Time Frame: Initial CAR T Infusion through Day 63 post infusion assessment (+/- 14 days)
|
Participants will be followed for 63 days to determine if the transferred T cells remain detectable in the blood and bone marrow
|
Initial CAR T Infusion through Day 63 post infusion assessment (+/- 14 days)
|
Number of Participants With Recrudescence or Development of Acute GVHD (Graft Versus Host Disease) Symptoms Post CAR T Infusion
Time Frame: Initial CAR T Infusion through Day 63 post infusion assessment (+/- 14 days)
|
Initial CAR T Infusion through Day 63 post infusion assessment (+/- 14 days)
|
|
Number of Participants That Received Cetuximab Who Have T Cells Successfully Ablated
Time Frame: 3 years
|
The efficacy of cetuximab to ablate the T cells will be measured by loss of detection of T cells and any associated toxicities as well as facilitating B cell recovery.
|
3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Colleen Annesley, MD, Seattle Children's Hospital
Publications and helpful links
General Publications
- Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
- Ceppi F, Wilson AL, Annesley C, Kimmerly GR, Summers C, Brand A, Seidel K, Wu QV, Beebe A, Brown C, Mgebroff S, Lindgren C, Rawlings-Rhea SD, Huang W, Pulsipher MA, Wayne AS, Park JR, Jensen MC, Gardner RA. Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects. Cancer Immunol Res. 2022 Jul 1;10(7):856-870. doi: 10.1158/2326-6066.CIR-21-0501.
- Finney OC, Brakke HM, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, Futrell RB, Orentas RJ, Li D, Gardner RA, Jensen MC. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019 Mar 12;129(5):2123-2132. doi: 10.1172/JCI125423. Print 2019 May 1.
- Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Kelly-Spratt KS, Hoglund V, Lindgren C, Oron AP, Li D, Riddell SR, Park JR, Jensen MC. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017 Jun 22;129(25):3322-3331. doi: 10.1182/blood-2017-02-769208. Epub 2017 Apr 13.
- Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG, Turtle CJ. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016 May 19;127(20):2406-10. doi: 10.1182/blood-2015-08-665547. Epub 2016 Feb 23.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PLAT-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CD19+ Acute Leukemia
-
Seoul National University HospitalRecruitingVery High Risk Acute Lymphoblastic Leukemia | CD19 CAR-T TherapyKorea, Republic of
-
Chinese PLA General HospitalUnknownRelapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACIChina
-
Hrain Biotechnology Co., Ltd.Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineRecruitingAcute Lymphoblastic Leukemia | CD19-positiveChina
-
Xijing HospitalXi'An Yufan Biotechnology Co.,LtdRecruitingLymphoma, B-Cell | CD19 Positive | Leukemia Lymphocytic Acute (ALL) in Relapse | Leukemia Lymphocytic Acute (All) RefractoryChina
-
Shanghai Longyao Biotechnology Inc., Ltd.UnknownThe Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Acute Lymphoblastic Leukemia (B-ALL) | Safety and Efficacy of CD19 UCAR-T CellsChina
-
Hebei Senlang Biotechnology Inc., Ltd.Hebei Yanda Ludaopei HospitalRecruitingCD19+ and CD 22+ B-ALLChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingPhiladelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | CD19 PositiveUnited States
-
Shanghai Unicar-Therapy Bio-medicine Technology...The First Affiliated Hospital of Soochow UniversityRecruitingAcute Lymphoblastic Leukemia | Relapse | CD19 Positive | RefractoryChina
-
First Affiliated Hospital Xi'an Jiaotong UniversityEureka Therapeutics Inc.UnknownCD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-CellChina
-
First Affiliated Hospital of Harbin Medical UniversityUnknownCD19-chimeric Antigen Receptor T Cells | Relapsed and/or Refractory Acute Lymphoblastic Leukemia | the Haploidentical Hematopoietic Stem Cell TransplantationChina
Clinical Trials on Patient Derived CD19 specific CAR T cells also expressing an EGFRt
-
Seattle Children's HospitalActive, not recruitingLeukemiaUnited States
-
Seattle Children's HospitalThe Evan Foundation; Ben Towne Center for Childhood Cancer ResearchActive, not recruitingNeuroblastoma | GanglioneuroblastomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingB Acute Lymphoblastic Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic LeukemiaUnited States
-
Chinese PLA General HospitalUnknown
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Seattle Children's HospitalActive, not recruitingCD 19+ Acute LeukemiaUnited States
-
Shenzhen Geno-Immune Medical InstituteThe Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...Recruiting
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Ependymoma | Medulloblastoma | Recurrent Metastatic Malignant Neoplasm in the LeptomeningesUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingDiffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin LymphomaUnited States
-
Seattle Children's HospitalActive, not recruitingLymphoma | LeukemiaUnited States, Canada